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Ampk regulates IgD expression 
but not energy stress with B cell 
activation
Lynnea R. Waters1,2, Fasih M. Ahsan 2, Johanna ten Hoeve3,4,5, Jason S. Hong2, 
Diane N. H. Kim6, Aspram Minasyan  3,5, Daniel Braas3,4,5, Thomas G. Graeber 3,4,5,7,8,9, 
thomas A. Zangle  10,11 & Michael A. teitell1,2,6,7,8,9,12
Ampk is an energy gatekeeper that responds to decreases in Atp by inhibiting energy-consuming 
anabolic processes and promoting energy-generating catabolic processes. Recently, we showed that 
Lkb1, an understudied kinase in B lymphocytes and a major upstream kinase for Ampk, had critical and 
unexpected roles in activating naïve B cells and in germinal center formation. Therefore, we examined 
whether Lkb1 activities during B cell activation depend on Ampk and report surprising Ampk activation 
with in vitro B cell stimulation in the absence of energy stress, coupled to rapid biomass accumulation. 
Despite Ampk activation and a controlling role for Lkb1 in B cell activation, Ampk knockout did not 
significantly affect B cell activation, differentiation, nutrient dynamics, gene expression, or humoral 
immune responses. Instead, Ampk loss specifically repressed the transcriptional expression of IgD and 
its regulator, Zfp318. Results also reveal that early activation of Ampk by phenformin treatment impairs 
germinal center formation but does not significantly alter antibody responses. Combined, the data 
show an unexpectedly specific role for Ampk in the regulation of IgD expression during B cell activation.
B lymphocyte activation is an early step in a humoral immune response, whereby a naïve B cell with a unique 
antigen receptor recognizes its cognate antigen to trigger growth, division, and differentiation. Following acti-
vation, selected B cells can develop into long-lived plasma cells that secrete antigen-specific antibodies to fight 
infections1. During receptor-mediated activation, B cells undergo class switch recombination (CSR), also called 
immunoglobulin isotype switching, to modify the type of B cell antigen receptor (BCR) expressed by the B cell, 
such as IgM or IgG1 isotypes2. Many of the early signaling events linked to engagement of the BCR are well 
studied3. Recently, we reported a role for the tumor suppressor Lkb1 in B cell activation: Lkb1 knockout (KO) 
caused spontaneous B cell activation in vivo without specific added antigenic stimulation, resulting in a robust 
T cell-dependent germinal center (GC) reaction4,5. This result was interesting because Lkb1 signaling had not 
been previously implicated in B cell activation and few models of spontaneous GC formation exist6. We therefore 
sought to determine the mechanism(s) whereby Lkb1 controls B cell activation.
Lkb1 phosphorylates 14 different related kinase family member proteins to control many cellular functions 
including protein synthesis and cell growth, cell polarity, and metabolism7. We elected to examine one of these 14 
major downstream Lkb1 targets, 5′ AMP-activated protein kinase (Ampk). Ampk is an energy sensor that couples 
metabolism with nutrient availability during periods of energetic stress, as might occur during rapid B cell expan-
sion and differentiation8. Ampk does this by sensing increasing levels of ADP or AMP with reducing levels of ATP 
in a cell, which triggers the phosphorylation of well characterized substrate proteins including Tsc2, Acc1/2, and 
Tbc1d1 to inhibit protein synthesis, promote fatty acid oxidation, upregulate glycolysis, and restore overall cell 
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energy balance9. While Lkb1 is the major upstream kinase for Ampk, other upstream kinases also phosphorylate 
Ampk including CamKK2 and Tak110–12. In T cells, CD3 ligation results in rapid Ampk activation in a calcium- 
and CamKK2-dependent manner13, and Ampk activation declines in proliferating normal T cells14; however, the 
Ampk activation pattern in B cells is unknown.
Studies of Lkb1 and Ampk have shown overlapping but also unique functions in hematopoiesis. For exam-
ple, Lkb1 maintains hematopoietic stem cell quiescence by regulating metabolism and the cell cycle using 
Ampk-dependent and -independent mechanisms15–17. In T cells and thymocytes, Lkb1 deletion reduced periph-
eral T cells and decreased T cell proliferation when stimulated in vitro. However, while loss of Ampk in T cells 
also led to metabolic and activation defects, it did not fully recapitulate the loss of Lkb118–20. There is only one 
reported study of Ampk in B cells, which showed that a whole mouse knockout of Ampk left isolated B and T cells 
unable to survive in vitro under oxidative stress when exposed to the ATP synthase inhibitor, oligomycin21. Given 
the unexpected role for Lkb1 loss in B cells in triggering a GC reaction, we sought to determine role(s) for Ampk 
during B cell activation.
Results
Ampk activation during B cell stimulation. Initially, we investigated whether Ampk, a major down-
stream target of Lkb1, was required for B cell activation4,5. Previous studies in T cells showed Ampk activation 
after T cell receptor stimulation13. We examined the phosphorylation of Ampk at T172, a marker residue for 
Ampk activation22 and determined that Ampk activation occurs between 18–24 hours post-stimulation of B cells 
with anti-CD40 antibody plus interleukin (IL)-4 that persists at least through 72 hours (Fig. 1A). Activation of 
Ampk should initiate cellular processes that halt the accumulation of biomass required for cell division9. Instead, 
anti-CD40 plus IL-4 stimulated B cells to divide rapidly between 48–72 hours (Fig. 1B). Ampk activation with 
energy stress has been reported many times and occurs by sensing decreasing amounts of ATP linked to increas-
ing ratios of AMP:ATP and ADP:ATP23. Therefore, we examined a previously published dataset of nucleotide 
metabolite levels at 24 hours post-stimulation. UHPLC-MS metabolomics data of 13C6-glucose nutrient labeling 
during initial B cell activation showed unexpected AMP:ATP and ADP:ATP ratios declining at 24 hours with ATP 
steady-state levels significantly increasing (Fig. 1C)24. Additional measurements of extracellular nutrients shows 
maintenance of high levels of both glucose and glutamine in the culture medium (Fig. 1D), indicating that Ampk 
activation occurs in stimulated B cells during energy replete conditions.
Since Ampk activation typically inhibits protein, lipid, and additional biosynthetic processes, we turned to live 
cell interferometry, a form of quantitative phase microscopy, as a high precision and reproducible approach to 
quantify changes in biomass accumulation during early B cell activation25 (Fig. 1E). We discovered that isolated 
naïve mouse B cells steadily increase cell biomass over the first 48 hours of anti-CD40 plus IL-4 stimulated activa-
tion (Fig. 1F). Interestingly, the specific growth rate calculated as a percentage of biomass change per hour accel-
erates for the first 18 hours and then plateaus (Fig. 1G). This growth rate peak coincides with the timing of Ampk 
activation (Fig. 1A), although despite Ampk activity B cells continue to acquire biomass at the peak (plateau) rate. 
This growth rate profile suggests that Ampk activation may damp further growth rate acceleration, perhaps as a 
rate-limiting step, but does not impede the overall growth of B cells.
Ampk is not required for B cell activation or differentiation. It was a surprise that Ampk was acti-
vated in stimulated naïve mouse B cells because a major role for Ampk in inhibiting lipid and protein synthesis 
seems incompatible with the high growth rate and cell division of activated B cells. Thus, we sought to determine 
whether Ampk was required for B cell activation and differentiation by generating a mouse model with B cell 
specific deletion of Ampk. Because Ampkα1, encoded by Prkaa1, is the only α subunit expressed in trimeric 
Ampk proteins in mature B cells26, deletion of this catalytic subunit abolishes all Ampk activity. We generated 
a B cell specific Ampkα1 KO mouse line by crossing Prkaa1fl/fl mice with CD19-Cre recombinase driver mice 
to delete Ampk activity in post-pro/pre B cells. To monitor deletion efficiency, we crossed mice with a Rosa26 
lox-STOP-lox YFP reporter allele (Fig. 2A). Deletion efficiency measured by YFP+ B220+ B cells was >80% in 
both WT (Prkaa1+/+ × CD19-Cre) and Ampk KO (Prkaafl/fl × CD19-Cre) mice (Fig. 2B), suggesting that there is 
no B cell survival disadvantage with loss of Ampk, in contrast to a major B cell survival disadvantage with Lkb1 
loss4. Analysis of lysates from naïve and anti-CD40 plus IL-4 stimulated WT and Ampk KO B cells confirmed 
loss of Ampkα1 protein and abolishment of Ampk activity in Ampk KO B cells (Fig. 2C). Use of a pan-Ampk 
alpha (α1 and α2) antibody also allows us to conclude that there was no compensatory expression of the Ampkα2 
subunit upon deletion of Ampkα1.
To determine whether Ampk deletion affects B cell activation, we stimulated isolated WT and Ampk KO B 
cells with anti-CD40 plus IL-4 and assessed activation and differentiation of YFP+ B cells. Surprisingly, despite 
Ampk activation at 24 hours, no changes in the levels of expression of activation markers CD69, CD86 or MHCII 
occur for the Ampk KO B cells compared to WT B cells. At later time points, no changes in GC-like B cell differ-
entiation at day 3 and a minor reduction in CSR to IgG1 occurred in Ampk KO compared to WT B cells. By day 
5, there was a small trending increase in plasmablast differentiation in Ampk KO versus WT B cells (Fig. 2D). 
These data strongly contrast with deletion of Lkb1 in B cells, which causes opposing results including increased 
activation marker expression and GC-like B cell differentiation, an increase in CSR, and a decrease in plasmablast 
differentiation4. Together, the results suggest that Ampk is not required for normal B cell function and is not 
required for Lkb1-dependent B cell phenotypes.
Ampk does not control a humoral immune response in vivo. We next examined whether Ampk 
deletion from B cells affects antibody responses in vivo. A prior study showed that whole mouse KO of Ampk did 
not affect IgG responses to Ars-KLH antigen in vivo21; however, other potential effects on the GC reaction, CSR, 
or antibody specificity were not examined. We inoculated Ampk KO and WT mice with the T cell-dependent 
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Figure 1. Activation of Ampk upon stimulation of B cells is independent of energy stress and does not result in 
lowered biomass accumulation. (A) Representative time course western blot for phosphorylated Ampkα (T172), 
Ampkα, and β-tubulin during anti-CD40 plus IL-4 stimulation of B cells. Image was cropped for clarity, full-length 
blots/gels are presented in Supplementary Fig. 1. (B) Representative flow cytometry of B220+ B cells at 0, 24, 
48 and 72 hours post anti-CD40 plus IL-4 stimulation stained with Cell Trace Violet. (C) Relative fold change in 
previously published UHPLC- MS metabolomics dataset24 for adenine nucleotides from 24 hours post stimulation 
with anti-CD40 plus IL-4 relative to naïve B cells (n = 3). (D) Measurement of extracellular glucose and glutamine 
at 24 hours post stimulation with anti-CD40 plus IL-4 (n = 3). (E) Live cell interferometry (LCI) images of 
anti-CD40 plus IL-4 activated B cells 1, 24, and 48 hours post stimulation showing significant growth, as confirmed 
by (F) a significant increase in average cell mass over time, binned into 3 h increments. (G) Average specific growth 
rate, computed as the instantaneous slope of mass over time for each cell normalized by cell mass, shows a peak at 
24 hours, coincident with Ampk inactivation (n = 5 independent experiments of at least 200 cells). Data represent 
mean ± SD (C,D) or SEM (F,G). P values determined by 2-way ANOVA with Bonferroni correction for multiple 
comparisons (C) or an unpaired two-tailed Student’s t-test (D). **P ≤ 0.01.
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antigen, NP-(28)-CGG, and analyzed B cells on day 14 post-immunization. We observed no differences in GC 
formation or CSR (Fig. 2E), and serum IgG1 levels were similar between WT and Ampk KO mice, with a slight 
but statistically insignificant difference in total IgM (Fig. 2F). Multivalent NP antigen enables detection of highly 
specific antibodies by probing for binding to specific NP molar ratios, with fewer NP molecules revealing higher 
specificity responses. Our data show that both broad spectrum and highly specific IgG1 against NP antigen were 
similar in WT and Ampk KO mice (Fig. 2F). These results show that Ampk is dispensable for a T cell-dependent 
humoral immune response, although Ampk may be critical in other contexts, such as T cell-independent, 
mucosal, or antiviral immune responses.
Figure 2. Ampk deletion does not significantly impair B cell function. (A) Strategy for generating B-cell 
lineage specific knockout of Prkaa1 by crossing CD19-Cre recombinase (JAX: 006785) mice with Prkaa1fl/fl 
(JAX: 014141) mice and Rosa26 lox-STOP-lox YFP (JAX: 006148) mouse lines, yielding mice where CD19+ B 
cells lack the catalytic Ampkα subunit. (B) Quantification of Cre-recombinase efficiency by measurement of 
percentage of B220+ B cells that have YFP expression by flow cytometry in WT and Ampk KO B cells (n = 3). 
(C) Representative Western blot for P-Ampkα (T172), Ampkα and β-tubulin in WT and Ampk KO mice. 
Two exposures are shown for Ampkα to illustrate some remaining Ampk expression. Image was cropped for 
clarity, full-length blots/gels are presented in Supplementary Fig. 2. (D) Flow cytometry of WT and Ampk KO 
B cells during activation with anti-CD40L plus IL-4, including activation markers (MHCII, CD86, CD69) at 
24 hours, GC differentiation (GC, %B220+ Fas+ GL7+) and CSR (%B220+ IgG1+) at day 3, and plasmablast 
differentiation (%B220lo CD138+) at day 5 (n = 5 for MHCII, CD86, CD69, and PB, n = 6 for GC, and n = 7 
for CSR). (E) Flow cytometry of total splenocytes after immunization. Representative plots and quantification 
of GC differentiation (GC B Cells, B220+ Fas+ GL7+) and CSR (B220+ IgG1+) 14 days post-immunization 
with NP-(28)-CGG (n = 4). (F) Total IgM, total IgG1, NP8 IgG1, NP20 IgG1, and NP8/NP20 IgG1 ratio in 
serum 14 days after immunization of WT and Ampk KO mice with NP-(28)-CGG (n = 4). (G) Representative 
flow cytometry for 2NBDG glucose uptake at day 1, 3, and 5 post stimulation with anti-CD40 plus IL-4, and 
quantification at day 0 through 5 in WT and Ampk KO B cells (n = 3). Data represent mean ± SD (B,D–G).  
P values determined by Student’s t-test (B,D–G), *P ≤ 0.05.
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Ampk is dispensable for activation-induced glucose uptake. While we did not detect differences 
in differentiation patterns of WT and Ampk KO B cells, B cell activation in response to a range of triggering 
stimuli causes increased glucose import24,27,28 and the deletion of Ampk in T effector cells reduces glucose uptake 
in vivo29. Therefore, we hypothesized that Ampk KO B cells might have defects in glucose uptake. To test this 
postulate, we utilized a fluorescent glucose analog, 2-NBDG, to measure glucose import in B cells from WT and 
Ampk KO mice that lack the Rosa26 lox-STOP-lox YFP tracer, because YFP and 2-NBDG fluorophore emission 
spectra overlap (527 nm and 540 nm, respectively). Unexpectedly, there was no difference between Ampk KO and 
WT B cells in glucose uptake during 5 days of B cell activation (Fig. 2G). Thus, Ampk activation does not regulate 
glucose import into activated B cells, suggesting an alternative glucose import mechanism.
Ampk does not affect glucose or glutamine B cell nutrients. While we did not detect differences 
in glucose uptake in Ampk KO B cells, Ampk also regulates other metabolic pathways to regulate energy stress, 
and Ampk activation at 24 hours of stimulation may impact nutrient choice or routing without affecting B cell 
differentiation or antibody responses. Therefore, we performed metabolomics profiling with 13C6-glucose and 
13C5-glutamine in resting and anti-CD40 plus IL-4 stimulated WT and Ampk KO B cells (Table S1). Principal 
component analysis (PCA) of total intracellular metabolites revealed that the major segmentation was from 
differences between stimulation time points, and not from differences between genotypes within each time 
point (Fig. 3A). We generated correlation circle plots by fitting each of the metabolites to 4 vectors based on 
the observed clustering (Fig. 3B), which indicated metabolites that are known to be changed upon activation, 
including increases in ATP with activation and decreases in the AMP/ATP ratio, consistent with prior results 
(Fig. 1C)24. With no significant differences in total metabolites between WT and Ampk KO B cells at rest or for 
any stimulated time point, we next analyzed specific 13C-isotopomer labeling. PCA of molecular IDs for isotopo-
mers (Fig. 3C, top) derived from the glucose label (left) or glutamine label (right) showed similar segmentation to 
the total metabolites, with the largest differences from stimulation time point rather than from genotype. We then 
assessed whether any biologically relevant metabolites were different between WT and Ampk KO at each time 
point. As a discovery tool, we plotted the non-corrected P-values for naïve, resting (middle row) and anti-CD40 
plus IL-4 stimulated (bottom row) B cells labeled with glucose (left) or glutamine (right) (Fig. 3C). The data failed 
to identify any biologically relevant differentially produced isotopomers (DPIs) linked to known functions of 
Ampk. These labeling patterns occurred despite >90% uptake of labeled glucose or glutamine in each respective 
experiment for all conditions examined (Fig. 3D). To further investigate whether there were any DPIs between 
WT and Ampk KO B cells irrespective of time point, we calculated P-values and could not identify metabolites 
below the corrected false discovery rate of 0.05 (Fig. 3E). We considered that some broad metabolic differences 
may not be discernible at the individual DPI level, and small changes may accumulate and reveal deficiencies or 
surpluses in whole pathways. We therefore performed Metabolite Set Variation Analysis (MSVA) utilizing curated 
KEGG metabolic pathways and again identified significant changes occurred only between naïve and stimulated 
B cells, with no separation by genotype (Fig. 4F). Together, these results show that Ampk is not modulating 
metabolism during B cell activation, despite known metabolic roles related to glucose metabolism.
Ampk regulates IgD levels but not transcripts controlling B cell fate. Additional canonical Ampk 
substrates include Hdac4 and Hdac5, proteins that deacetylate histones and thereby regulate gene expression30. 
To assess potential differences in steady-state RNA expression, and to investigate potential alternative processes 
regulated by Ampk, we performed RNA-Seq in WT and Ampk KO B cells on culture days 0 through 5 using 
anti-CD40 plus IL-4 stimulation (Table S2). At day 0, there are no PCA plotted statistical differences between 
WT and Ampk KO naïve B cells. However, as B cells differentiate from day 1 through day 5, Ampk KO B cells 
cluster separately from their WT counterparts, but follow a similar trajectory towards differentiation (Fig. 4A). 
We confirmed reduced Prkaa1 expression in Ampk KO B cells, as expected (Fig. 4B). To determine whether loss 
of Ampk conveyed a specific gene signature during 5 days of differentiation, we analyzed differentially expressed 
genes (DEGs) for days 0 through 5 of stimulation and identified 168 genes that were either consistently increased 
or decreased each day in Ampk KO compared to WT B cells (Fig. 4C). Pathway enrichment analysis of these 
168 genes did not reveal any pathways related to B cell activation or differentiation, with the exception of 5 
genes linked to apoptotic signaling in response to endoplasmic reticulum stress (Grina, Atf4, Trib3, Lrrk2, Chac1) 
(Table S2). Endoplasmic reticulum stress has an important role in plasma cell differentiation and antibody secre-
tion31. Therefore, we analyzed activation, GC B cell, and antibody-secreting cell (ASC) gene expression signa-
tures32,33 as previously reported in our data set (Fig. 2D). Similar to our earlier data, Ampk KO and WT B cells 
activate similarly and increase GC-signature transcripts equally. Expression of ASC signature genes were similar 
between WT and Ampk KO samples (Fig. 4D), although Ampk KO B cells showed increases in some ASC tran-
scripts, including Prdm1 at days 4 and 5 (Fig. 4D). This finding is consistent with a trend towards an increase in 
plasmablasts at day 5 (Fig. 2D), and a divergence in the PCA plot of days 4 and 5 WT versus Ampk KO B cells 
(Fig. 4A).
Because of the potential for increased ASCs in Ampk KO mice, despite similar amounts of secreted IgM and 
IgG1 from in vivo immunizations (Fig. 2F), we evaluated the levels of immunoglobulin transcripts in WT and 
Ampk KO B cells. We determined that heavy chain variable (Ighv) region expression levels were similar for WT 
and Ampk KO B cells, although there was an increase in some transcripts including Ighv6-3 and Ighv14-3 in 
Ampk KO B cells (Fig. 5A). From in vivo immunization data, we also detected a slight but insignificant increase 
in secreted IgM, so we analyzed transcripts for immunoglobulin constant regions to identify potential isotype 
biases. Whereas Ighm transcripts matched our observations in vivo with a minor but insignificant increase at day 
5 for Ampk KO versus WT B cells, we were surprised to discover that Ighd expression was severely repressed in 
Ampk KO B cells from day 1 stimulation onwards (corrected P-value = 9.5 × 10−30 at day 1) (Fig. 5B). IgD is nor-
mally co-expressed with IgM on the surface of all mature, naïve B cells, and is a relatively understudied antibody 
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Figure 3. Ampk does not control metabolism during B cell stimulation. (A) PCA from UHPLC-MS metabolomics 
analysis of total metabolites isolated from naïve and stimulated B cells from WT and Ampk KO mice. (B) K-means 
clustering analysis of variable loading plots, indicating the contribution of metabolites to variation across principal 
components in four groups (k = 4). Projection arrow tips indicate Pearson correlation of the listed metabolite. 
Transparency denotes cosine2 value or the strength of metabolite representation. Shown are the top 4 metabolites 
contributing to each cluster. (C) Principal component analysis and volcano plots of UHPLC-MS metabolomics 
of 13C6-glucose labeled or 13C5-glutamine labeled isotopomers (MID) in naïve and stimulated B cells from WT 
and Ampk KO mice. Plotted are non-corrected P values for KO/WT amounts of specific isotopomers (n = 3). 
(D) Isotopomer distribution of labeled glucose or labeled glutamine in naïve or stimulated WT and Ampk KO B 
cells shows uptake of labeled respective carbon source. (E) Quantification of Differentially Produced Isotopomers 
(DPIs) analyzed both by day and by genotype shows no DPIs between genotypes, only between time points for 
uncorrected or Benjamini-Hochberg corrected P values < 0.05. (F) Heatmap of significant (Benjamini-Hochberg 
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class that has potential implications in mucosal immune responses34. The expression of IgD is not impacted by 
activation-induced cytidine deaminase (AID) like most isotype switched immunoglobulins but is instead regu-
lated by Zfp31835,36. Interestingly, the most robust DEGs at day 3 are Ighd and Zfp318, each of which are greater 
than an order of magnitude more repressed than the next most differentially expressed genes (Fig. 5C). In fact, 
Zfp318 expression is repressed throughout the stimulated time course in Ampk KO B cells (Fig. 5D), coinciding 
with the drop in Ighd expression (Fig. 5B). Further supporting the specificity of Ampk loss on Zfp318 regulation 
of Ighd levels, expression of Aicda, encoding AID which regulates CSR, is the same in WT and Ampk KO B cells 
from days 0–4 and increased on day 5 of B cell activation (Fig. 5D). To confirm that the loss of Ighd transcripts 
affects IgD protein levels, we analyzed surface expression over 5 days of differentiation by flow cytometry, which 
shows that Ampk KO B cells have decreased IgD expression from days 2 through 5, particularly evident for the 
loss of IgD-high B cells (Fig. 5E). Given the limited number of DEGs, it appears that Ampk exerts highly specific 
control of IgD during B cell activation, likely through regulation of Zfp318 expression.
Pharmacological activation of Ampk. The limited scope of impact for Ampk loss on B cell physiology 
seems surprising, so we examined whether the timing of Ampk activation could regulate B cell functions. We uti-
lized two pharmacological activators of Ampk, phenformin and A-769662, to alter the timing of Ampk activation. 
Phenformin is a mitochondrial electron transport chain complex I inhibitor that activates Ampk by inhibiting 
ATP production, thereby increasing AMP/ATP and ADP/ATP ratios, and is an analogue of the diabetes drug 
metformin, whereas A-769662 is a direct and specific activator of Ampk23. We examined early activation of Ampk 
by treating B cells with each activator at the time of anti-CD40 plus IL-4 stimulation in culture and observed that 
both drugs decreased CD86 activation biomarker expression, but only phenformin reduced CD69 expression 
(Fig. 6A). Phenformin had a drastic effect on B cell differentiation by day 3 with greatly decreased CSR to IgG1 
and inhibited differentiation into GC-like B cells (Fig. 6B). By contrast, A-769662 had little effect on GC-like B cell 
differentiation and only a slight defect in CSR (Fig. 6B). These results show that electron transport chain activity 
and ATP production per se, and not accelerated Ampk activation, are critical for B cell activation, differentiation, 
and CSR, in agreement with an effect mainly targeting markedly reduced Zfp318 and Ighd expression levels in 
stimulated Ampk KO B cells (Fig. 5).
Because of recent interest in using metformin and phenformin clinically to treat B cell malignancies37, we 
further evaluated the impact of phenformin on B cell function. To determine whether the effects of phenformin 
in vitro replicate in vivo, we immunized mice with NP-(28)-CGG to induce a T cell-dependent humoral immune 
response while delivering phenformin or sucralose vehicle in the drinking water (Fig. 6C). In vivo results show 
that 14-day treatment with phenformin substantially decreased the percentage of GC B cells in the spleen and 
reduced the percentage of IgG1+ isotype switched B cells (Fig. 6D). Interestingly, however, mice on phenformin 
had similar amounts of total IgM and IgG1 in their serum (Fig. 6E). There was a minor but non-significant 
defect in the generation of NP8-specific high affinity IgG1 antibody in phenformin treated mice, but no effect on 
broader NP20 IgG1 antibodies (Fig. 6F). Overall, these findings suggest that phenformin reduces GC formation, 
but still allows for generation of antigen-specific antibody production.
Discussion
Our recent results showing that loss of Lkb1 kinase signaling triggers the B cell GC reaction4,5 prompted studies 
of Ampk as a main Lkb1 target kinase during B cell activation. We found Ampk activation 24 hours after stimu-
lation of naïve B cells with anti-CD40 antibody plus IL-4 (Fig. 1A). A key role for activated Ampk in mammalian 
cells is to block anabolic processes that consume energy by target protein phosphorylation in response to energy 
stress. To our surprise, B cell activation with rapid biomass accumulation and cell proliferation coincides with 
sustained Ampk activation in the absence of energy stress (Fig. 1A,B). We anticipated the opposite result, that 
Ampk activity would prevent biomass accumulation. While unexpected given the canonical targets and activities 
of Ampk, including inhibition of major anabolic targets Acc1, Tsc2, and Raptor, these findings also make sense 
in the biological context of B cell activation. For example, the Ampk target Raptor is essential for Bcl6 expression 
and recruitment of activated B cells into GCs38, and inhibition of Raptor by Ampk at this time would prevent 
GC formation. Similarly, Ampk-driven inhibition of protein and lipid synthesis through Acc1 and Tsc2 would 
antagonize the need for biomass accumulation while B cells prepare for rapid division in the GC24,39,40. While acti-
vation of Ampk during B cell activation was unexpected due to the role of Ampk in biomass accumulation, there 
are precedents for Ampk activation in other immune contexts. For example, in T cells, Ampk is transiently and 
immediately activated after CD3 or calcium stimulation13, and Ampk phosphorylation declines in proliferating 
T effector cells14. This contrasts with B cells, where Ampk activation after 24 hours of stimulation persists dur-
ing proliferation (Fig. 1A). In T cells, Ampk activation by nutrient limitation, metformin treatment, or AICAR, 
results in decreased IFN gene transcription and reduced T cell effector function29. Here, activation of Ampk by 
phenformin prevents GC differentiation and CSR, but still allows for generation of high-specificity antibodies 
(Fig. 6A–E).
FDR adjusted P value < 0.05) metabolite set variation analysis (MSVA) pathway activity scores across WT and 
Ampk KO naïve and stimulated B cells for curated KEGG metabolic pathways. Data represent the mean ± SD (D) 
of relative metabolite amounts from n = 3 independent experiments. Data from separate glucose and glutamine 
labeling experiments were pooled, and relative amounts analyzed for (A,B). P values determined by Student’s t test 
(C), 2-way ANOVA with Bonferroni correction for multiple comparisons (D), or empirical Bayes with Benjamini-
Hochberg correction for multiple comparisons (F).
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To study Ampk during B cell activation in vivo, we made a B cell specific KO of the catalytic Ampk alpha sub-
unit, Prkaa1 that achieved >80% deletion efficiency, but did not detect a phenotype similar to B cell specific Lkb1 
KO mice4. In fact, Lkb1 loss increases CSR and decreases plasmablast differentiation, whereas Ampk loss instead 
decreases CSR and slightly increases plasmablast differentiation (Figs 2D, 4D). These results suggest that Lkb1 
acts through substrates other than Ampk to regulate B cell activation and GC formation, or that other related 
Lkb1 targets may compensate for the loss of Ampk. For example, Lkb1 phosphorylates 13 other Ampk family 
member proteins including Mark, Brsk, and Nuak proteins7. Sik2 and Mark2 are Lkb1 targets that phosphorylate 
Crtc241, a transcriptional co-activator of CREB required for GC exit42, and their redundant activity might com-
pensate for the loss of Ampk to rescue plasma cell differentiation.
We were further surprised to find no evidence for Ampk in regulating metabolism in B cells. Nutrient uptake 
and routing was identical in WT and Ampk KO B cells (Figs 2G, 3). One possibility is that Ampk is dispensable for 
Figure 4. B cell activation and differentiation expression signatures are maintained despite loss of Ampk. (A) 
PCA from bulk RNA sequencing analysis of total RNA isolated from day 0 through day 5 stimulated B cells 
from WT and Ampk KO mice. PC1 and PC2 are shown. (B) Kinetic time course expression plot of Prkaa1 
during stimulation. (C) Heat map of KO signature gene expression across averaged samples. KO signature 
was generated as the intersection of all KO/WT DEGs at each time point from day 1 to day 5 of stimulation 
(adjusted P value < 0.05, abs(log2FC) >0.5 at each time point comparison). (D) Heat maps for B cell activation, 
germinal center, and ASC gene signatures from32,33,55. Genes shown were selected as the top 55 differentially 
expressed from the Shi 2015 signatures between WT day 0 and day 2 (activation), WT day 0 and day 3 (GC), 
and WT day 0 and day 5 (ASC), with Prdm1 included post hoc. Pathway scores represent total GSVA enrichment 
of the respective Shi 2015 signatures for each comparison (adjusted P value < 0.05). Heat map values represent 
row z-score (n = 3 each WT and KO for each time point). Adjusted P values determined by Wald test (B). 
****P ≤ 0.0001.
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homeostatic nutrient handling but required for metabolic adaptations under stressful conditions not examined 
here. Supporting this idea, studies in T cells show that Ampk can regulate glutamine metabolism during glucose 
deprivation29 and total body knockout of Ampk makes B and T cells unable to survive ATP synthase inhibition 
with oligomycin21. Recent studies show that GCs in mice are hypoxic microenvironments43 and Ampk links to 
inflammation in hypoxia44. Resting and activated Ampk KO B cells express genes and gene profile signatures sim-
ilar to WT B cells, except for two repressed transcripts, Zfp318 and Ighd. This specificity is remarkable and rep-
licates the specificity of Zfp318 KO B cells, in which there were only two differentially expressed genes, Ighd and 
Figure 5. Ampk specifically regulates expression of IgD via downregulation of Zfp318 during activation. (A) 
Heat maps for immunoglobulin heavy-chain variable region expression (Ighv) across naïve and day 4/day 5 
stimulated B cells. Genes were selected based on significant differential expression between WT naïve and day 5 
stimulation (adjusted P value < 0.05). Values represent row z-score. (B) Kinetic time course expression plots for 
immunoglobulin heavy-chain constant region (Igh) expression across genotype and stimulation. (C) Volcano 
plot of differentially expressed genes between Ampk KO and WT at day 3 of stimulation. Adjusted P value 
cutoff represents values < 0.05 calculated using the Wald test following DESeq2 normalization. (D) Kinetic time 
course expression plot of Zfp318 and Aicda across genotype and stimulation. (E) Representative flow cytometry 
plot of IgD at day 0 through day 5 of stimulation in WT and Ampk KO B cells and quantification by MFI (top) 
and % IgD (bottom) (n = 3 each WT and Ampk KO). P values were determined by Student’s t-test (E), adjusted 
P values were determined by Wald test (B,D) *P ≤ 0.05, **P ≤ 0.01, **P ≤ 0.001, ***P ≤ 0.0001.
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Figure 6. Early pharmacological activation of Ampk modifies B cell function both in vitro and in vivo. (A,B) 
Representative flow cytometry plots and quantification of activation markers (CD86, CD69) at 24 hours (A), and 
germinal center differentiation (GC B Cells, %B220+ Fas+ GL7+) and class switch recombination (CSR, %B220+ 
IgG1+) at day 3 (B) of cells during in vitro activation with anti-CD40 plus IL-4 and phenformin (100 µM) or 
A-769662 (50 µM) (n = 3). (C) Strategy for in vivo assessment of B cells responses with Ampk activation. Prior to 
immunization, mice were given phenformin or vehicle (sucralose) in their water. Water was changed 2×/week, and 
samples collected 14 days post immunization with NP-(28)-CGG. (D) Flow cytometry of total splenocytes after 
immunization. Representative plots and quantification of GC differentiation (GC B Cells, B220+ Fas+ GL7+) and 
CSR (B220+ IgG1+) 14 days post-immunization with NP-(28)-CGG (n = 4). (E) Anti-NP8 and anti-NP32 IgG1 
serum response and NP8/NP32 IgG1 ratio by ELISA 14 days after immunization with NP-(28)-CGG (n = 4). Data 
represent mean ± SD. P values determined by 2-way ANOVA with Bonferroni correction for multiple comparisons 
(A,B), or Student’s t-test (D,E), *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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Sva, an antigen related to the Vav-Cre recombinase deletion construct35. Loss of Ighd transcripts parallels a loss of 
surface IgD protein expression in the Ampk KO B cells after stimulation. A possible but less likely contributor to 
a difference in later time point IgD expression between WT and Ampk KO B cells could be differential increase in 
cell death in the in vitro culture system between days 4 and 5 of stimulation. The role(s) of IgD in B cells remains 
elusive, as IgD is present at very low levels in human and rodent serum45, but has recently been suggested to 
modulate Th2 responses to soluble antigens through interactions with basophils46. Because of co-expression of 
IgM and IgD in immature B cells, IgD may sequester signaling molecules from IgM to inhibit BCR signaling47, 
and IgD may play a similar role in mature B cells. Regardless of the role of IgD, the specific regulation of Zfp318 
and Ighd by Ampk provides new insight into immunoglobulin gene regulation as a non-canonical role for Ampk.
Materials and Methods
Mice. C57BL/6J, Prkaa1fl/fl, CD19-Cre, and Rosa26 lox-STOP-lox EYFP mice (JAX: 000664, 014141, 006785, 
and 006148) were housed in a specific pathogen-free animal facility at UCLA. All studies were on mixed-sex mice 
between 6 to 16 weeks of age with approval from the UCLA Institutional Animal Research Committee (#1998-
113-63C). All experiments were performed according to the National Institutes of Health and ARRIVE guide-
lines on the use of laboratory animals. Figures 1, 6 used WT C57BL/6J mice, and Figs 2–5 used B cell specific 
Ampk KO or Ampk WT littermate mice. Genotypes for WT (Prkaa1+/+) and Ampk KO (Prkaa1−/−) mice were 
as follows: Prkaa1wt/wt or Prkaa1fl/fl, respectively, with CD19-Cre+/−, and Rosa26-YFP+/+ or +/− for experiments 
requiring YFP (Fig. 3B–D,F) or Rosa26-YFP−/− for experiments without YFP tracer (Figs 3E,F, 4–6).
Stimulation of isolated mouse B cells. Red blood cell-lysed mouse spleen cells were enriched for B cells 
using CD43 negative magnetic selection (Miltenyi). Cells were grown in RPMI1640 supplemented with 10% 
FBS and 50 μM β-mercaptoethanol. B cells were stimulated with 1 μg/ml anti-CD40 mAb (BD Pharmingen) and 
25 ng/ml IL-4 (R&D Systems). At day 3, anti-CD40 was washed out and cells replated in medium containing only 
IL-4 until day 5. For early Ampk activation, phenformin (Sigma) was resuspended in 1x PBS, pH 7.4, and used at 
100 µM, and A-769662 (Abbott) was resuspended in DMSO and used at 50 µM at the time of stimulation.
Immunoblotting. Cells were lysed in Lysis Buffer containing 50 mM Tris HCl pH 7.4, 100 mM NaCl, 1 mM 
EDTA and 1% Triton X-100 supplemented with Protease Inhibitor and Phosphatase Inhibitor Cocktails 2 and 
3 (Sigma). Extracts were quantified and denatured by boiling with DTT and 10–30 µg protein separated by 
SDS-PAGE and transferred to nitrocellulose before blocking in 5% milk in TBST. Membranes were incubated 
overnight in the indicated antibodies in 5% BSA in TBST. Membranes were then incubated in fluorescent second-
ary antibody and imaged using the Odyssey Fc imaging system (LI-COR). Complete antibody information can 
be found in the Supplemental Methods.
Flow cytometry. Single cell suspensions were incubated with Fc Block (BD Pharmingen) at 1:500 for 15 min, 
then washed and stained for 20 min in 50 µl FACS buffer (2% FBS in PBS) on ice in the dark. Data were obtained on a 
BD LSRII or BD Fortessa (BD Biosciences) and analyzed with FlowJo software (Treestar). Antibodies were used at a 
1:200 dilution. Complete antibody information can be found in the Supplemental Methods. Assessments of glucose 
import used a 2-NBDG Glucose Uptake Assay Kit (Biovision) according to the manufacturer’s instructions.
extracellular metabolite analysis. Glutamine levels in full media and after 24 hours of stimulation were 
measured by plating 106 cells/ml in 2 ml, centrifuging to remove cells and debris, and analyzing using a BioProfile 
Basic Analyzer (NOVA Biomedical).
Live cell interferometry. Live cell interferometry (LCI) was used to measure biomass accumulation rate25. Cells 
were plated at 7.5 × 105 cells/ml on Poly-L-Lysine (Sigma) coated μ-Slide 2-Well Ph+ glass bottom slides (Ibidi) and 
imaged every 15 min for 72 h in a custom-built chamber as previously described48. LCI was performed on a Zeiss 
Axio Observer A1 with stage-top incubation system (Zeiss) using using a 20 × 0.4 NA objective. LCI data were cap-
tured with a SID4Bio (Phasics) QWLSI camera49. MATLAB (Mathworks) was used to analyze LCI data. Quantitative 
phase microscopy data was processed using SID4Processing (Phasics) to generate phase-shift images compatible with 
MATLAB. A custom MATLAB script was used to track the mass of individual cells as previously described50.
Immunization and eLIsA. Mice were immunized with 50 µg NP-(28)-CGG (Biosearch Technologies) 
in ImJect Alum (Thermo Scientific) via intra-peritoneal injection. Blood was collected at 14 days and assayed 
by ELISA. Serum Ig concentrations were determined using anti-mouse Ig as a capture antibody and developed 
with isotype-specific goat anti-mouse antibodies conjugated to HRP (Southern Biotech). Antigen-specific ELISA 
was performed by coating a plate with NP-(8)- or NP-(20)-BSA and developed with an isotype specific goat 
anti-mouse antibody conjugated to HRP. For immunizations with phenformin, mice were given water containing 
either vehicle (5 mg/ml sucralose, Sigma) or phenformin (1.8 mg/ml, Sigma) with vehicle in amber bottles one 
day before immunization, and water was changed twice per week.
Metabolomics. B cells were grown for 24 hours in media with glucose or glutamine free RPMI (Gibco) sup-
plemented with 2 g/L [U-13C] glucose or 3 mM [U-13C] glutamine, respectively (Cambridge Isotope Laboratories) 
and non-dialyzed FBS. Metabolites were extracted with cold 80% methanol and measured using Ultra High 
Performance Liquid Chromatography Mass Spectrometry (UHPLC-MS), as previously described24,51,52. To 
extract intracellular metabolites, cells were pelleted by centrifugation (1000 RPM, 4 °C) and rinsed with cold 
150 mM ammonium acetate (pH 7.3), pelleted again, followed by addition of 1 ml cold 80% MeOH in water. To 
the cell suspensions, 10 nmol D/L-norvaline were added and rigorously mixed followed by centrifugation 
(1.3 × 104 rpm, 4 °C). The supernatant was transferred into a glass vial and pellet was further extracted with 200 µl 
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cold 80% MeOH in water. After centrifugation, supernatant was combined, metabolites dried down under vac-
uum, and resuspended in 70% acetonitrile. For the mass spectrometry-based analysis of the sample, 5 μl were 
injected onto a Luna NH2 (150 mm × 2 mm, Phenomenex) column. The samples were analyzed with an UltiMate 
3000RSLC (Thermo Scientific) coupled to a Q Exactive mass spectrometer (Thermo Scientific). The Q Exactive 
was run with polarity switching (+3.50 kV/−3.50 kV) in full scan mode with an m/z range of 65–975. Separation 
was achieved using A) 5 mM NH4AcO (pH 9.9) and B) ACN. The gradient started at 15% A) going to 90% A) 
over 18 min, followed by an isocratic step for 9 min and reversal to the initial 15% A) for 7 min. Metabolites and 
isotopomers thereof were quantified with TraceFinder 3.3 using accurate mass measurements (≤3 ppm) and 
retention times. For isotopologue distribution measurements, data was corrected for naturally occurring 13C as 
described in53. Fractional contributions were calculated using the formula = ∑
∑
⁎FC i m
n m
n
i
n
i
0
0
 as described54, where mi 
denotes the intensity of the isotopologue, and n marks the number of carbons in a given metabolite. Data were 
normalized to cell counts. Metabolite relative amounts, isotopomer distribution values, MSVA scores, and DPI 
lists are included in a supplemental excel file (Table S1).
RNA extraction. At least 107 WT and Ampk KO B cells were grown in biological triplicates and RNA purified 
immediately after isolation, or 24 hours after anti-CD40 plus IL-4 stimulation using the RNeasy Mini Kit (Qiagen) 
and RNase-free DNase (Qiagen) following the manufacturer’s protocols. All samples showed an A260/280 ratio 
>1.99. Prior to library preparation, quality control of the RNA was performed using the Advanced Analytical 
Technologies Fragment Analyzer (Advanced Analytical, Inc.) and analyzed using PROSize 2.0.0.51 software. 
RNA Quality Numbers (RQNs) were computed per sample between 8.7 and 10, indicating intact total RNA per 
sample prior to library preparation.
RNA-seq library preparation. Strand-specific ribosomal RNA (rRNA) depleted RNA-Seq libraries were 
prepared from 1 µg of total RNA using the KAPA Stranded RNA-Seq Kit with Ribo-Erase (Kapa Biosystems, 
Roche). Briefly, rRNA was depleted from total RNA samples, the remaining RNA was heat fragmented, and 
strand-specific cDNA was synthesized using a first strand random priming and second strand dUTP incor-
poration approach. Fragments were then A-tailed, adapters were ligated, and libraries were amplified using 
high-fidelity PCR. All libraries were prepared in technical duplicates per sample and resulting raw sequencing 
reads merged for downstream alignment and analysis. Libraries were paired-end sequenced at 2 × 150 bp on an 
Illumina NovaSeq 6000.
Lists of transcript/gene-level expression values, KO signature ORA results, and differentiation signature GSVA 
results are included in a supplemental excel file (Table S2).
statistical analyses. All metabolomics and transcriptomics statistical analyses are described in the above 
methods. Values represent mean ± S.D. or S.E.M. Data were analyzed with Prism 6 (GraphPad) (Figs 1–3, 6), 
MATLAB (Mathworks) (Fig. 1E–G) or R (Figs 3–5). Parametric data were analyzed using unpaired two-tailed 
Student’s t-tests, or 2-way ANOVA with Bonferroni correction for multiple comparisons. Transcriptomic volcano 
and kinetic time course expression plots were analyzed using DESeq2 Wald tests with Benjamini-Hochberg FDR 
correction for multiple comparisons. For all data sets, P ≤ 0.05 was considered significant. *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001, ****P ≤ 0.0001.
Data Availability
All raw RNA-Seq reads, transcript abundance values, and processed gene count matrices were submitted to the 
NCBI Gene Expression Omnibus (GEO) under accession GSE121025. All metabolomics and downstream tran-
scriptomics datasets have been provided as supplemental material in this study (Tables S1 and S2).
Code Availability
All custom code used for metabolomic/transcriptomic analyses are available on Atlassian BitBucket at http://bitbucket.
org/ahsanfasih/AmpkBcell/src/master and detailed descriptions of data analysis can be found in the Supplementary 
Methods.
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